<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959803</url>
  </required_header>
  <id_info>
    <org_study_id>B0401004</org_study_id>
    <nct_id>NCT00959803</nct_id>
  </id_info>
  <brief_title>Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.</brief_title>
  <official_title>An Investigator- And Subject-Blind Phase 1 Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04447943 After Administration Of Single Oral Doses To Healthy Young Adult Japanese Subjects And Multiple Oral Doses To Healthy Elderly Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the safety, tolerability, and pharmacokinetics of
      PF-04447943 after single and multiple-dose administration to healthy young adult and elderly
      Japanese subjects, respectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs (spontaneous and solicited). Change from baseline in vital signs.</measure>
    <time_frame>Day 0 to follow up visit after Study Day 5(single dose arm) and Day 11(multiple dose arm)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG and clinical safety laboratory endpoints, including a complete blood count, a full chemistry panel (including electrolytes and hepatic transaminases) and urinalysis.</measure>
    <time_frame>Screening visit to follow up visit after Study Day 5(single dose arm) and Day 11(multiple dose arm)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (single): AUClast, Cmax, Tmax</measure>
    <time_frame>Day 1 to day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic(multiple): AUCt, Cmax and Tmax on Days 1 and 7, and Ctrough on Days 2, 3, 4 and 7.</measure>
    <time_frame>Day 1 to day 11</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 way crossover with randomized placebo substitution to evaluate single escalating oral doses of PF 04447943 in 9 healthy young adult subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3:1 active PF 04447943 to placebo randomization in 8 healthy elderly subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04447943</intervention_name>
    <description>3 mg solution, oral single dose.</description>
    <arm_group_label>Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04447943</intervention_name>
    <description>10 mg solution, oral single dose.</description>
    <arm_group_label>Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04447943</intervention_name>
    <description>25 mg solution, oral single dose.</description>
    <arm_group_label>Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution, oral single dose.</description>
    <arm_group_label>Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04447943</intervention_name>
    <description>25 mg solution, oral twice daily for 7 days.</description>
    <arm_group_label>Multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution, oral twice daily for 7 days.</description>
    <arm_group_label>Multiple dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For young cohort, healthy male and/or female Japanese of non-child bearing potential
             between the age of 18 and 55 years, inclusive.

          -  For elderly cohort, healthy male and/or female Japanese of non-child bearing potential
             between the age of 65 and 85 years, inclusive.

          -  Body Mass Index (BMI) between 17.5 to 30.5 kg/m2, and a total body weight &gt;50 kg (110
             lbs).

        Exclusion Criteria:

          -  Pregnant or nursing women; women of childbearing potential.

          -  Males who are unwilling to abstain from sexual intercourse or use a condom with all
             child-bearing potential women for the duration of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0401004&amp;StudyName=Study%20Of%20Single%20Ascending%20And%20Multiple%20Doses%20Of%20PF-04447943%20In%20Japanese%20Subjects.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2009</study_first_submitted>
  <study_first_submitted_qc>August 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2009</study_first_posted>
  <last_update_submitted>December 3, 2009</last_update_submitted>
  <last_update_submitted_qc>December 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy Young Adult</keyword>
  <keyword>Japanese</keyword>
  <keyword>Healthy Elderly</keyword>
  <keyword>Alzheimer disease</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

